One piece of the puzzle: Population pharmacokinetics of FVIII during perioperative Haemate P^® /Humate P^® treatment in von Willebrand disease patients.

ABSTRACT:

Introduction

Many patients with von Willebrand disease (VWD) are treated on demand with von Willebrand factor and factor VIII (FVIII) containing concentrates present with VWF and/or FVIII plasma levels outside set target levels. This carries a risk for bleeding and potentially for thrombosis. Development of a population pharmacokinetic (PK) model based on FVIII levels is a first step to more accurate on-demand perioperative dosing of this concentrate.

Methods

Patients with VWD undergoing surgery in Academic Haemophilia Treatment Centers in the Netherlands between 2000 and 2018 treated with a FVIII/VWF plasma-derived concentrate (Haemate® P/Humate P®) were included in this study. Population PK modeling was based on measured FVIII levels using nonlinear mixed-effects modeling

SUBMITTER: de Jager NCB 

PROVIDER: S-EPMC7028136 | biostudies-literature | 2020 Feb

REPOSITORIES: biostudies-literature